Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06063538 · ClinicalTrials.gov registry record · Early Phase 1
Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone
A Early Phase 1 study of Atrial Fibrillation and Post-Op Complication, sponsored by University of Chicago.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT06063538: Recruiting Early Phase 1 study of Atrial Fibrillation and Post-Op Complication, sponsored by University of Chicago.
NCT06063538 is a Early Phase 1 study of Atrial Fibrillation and Post-Op Complication that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 63 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06063538, a Early Phase 1 study of Atrial Fibrillation and Post-Op Complication, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing cardiac arterial bypass grafting (CABG) or valve surgery.
Primary Outcome
The patients have continuous electrocardiogram (EKG) monitoring until discharge to evaluate for any evidence of atrial fibrillation or atrial flutter which lasts longer than one hour or if less than one hour, requires medical or procedural intervention. Evidence of atrial fibrillation or atrial flutter will be confirmed by 12 lead electrocardiogram by loss or changes to the P wave, as well as irregularities in the QRS wave interval, heart rhythm, or rate. If clinically indicated, patients will r
Conditions Studied
Interventions
- COMBINATION_PRODUCT CardiaMend in Combination with Amiodarone
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2027-06 |
| Phase | Early Phase 1 |
What NCT06063538 shows while recruiting
NCT06063538 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which CardiaMend in Combination with Amiodarone is the first listed.
NCT06063538 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06063538 about?
NCT06063538 is a clinical study titled "Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone". The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing cardiac arterial bypass grafting (CABG) or valve surgery.
What is the current status of trial NCT06063538?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 63 participants. The study started on 2024-02-15. Estimated completion is 2027-06.
What conditions does trial NCT06063538 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Post-Op Complication.
What interventions are being tested in trial NCT06063538?
The interventions under investigation include: CardiaMend in Combination with Amiodarone (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06063538?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06063538 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06063538's enrollment target sits among peer trials
63 163rd of 202 higher than 39 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI